Novo Nordisk(US:NVO) Prnewswire·2025-11-06 19:30Core Insights - Novo Nordisk presented new post hoc analyses from the phase 3 REDEFINE 1 trial for CagriSema, an investigational treatment for obesity, highlighting its potential cardiovascular risk reduction effects [1][15]. Group 1: Clinical Efficacy - CagriSema treatment resulted in a reduction of systolic blood pressure by -10.9 mmHg over 68 weeks, outperforming semaglutide (–8.8 mmHg) and placebo (–2.1 mmHg) [2][6]. - Approximately 40% of participants on blood pressure medications were able to reduce or stop their medication during the trial [2][6]. - CagriSema demonstrated a significant reduction in high-sensitivity C-reactive protein (hsCRP) by –68.9%, compared to –55.4% with semaglutide and –16.0% with placebo, indicating anti-inflammatory effects [3][6]. Group 2: Cardiovascular Risk - The treatment reduced the proportion of individuals at intermediate-to-high risk of developing atherosclerotic cardiovascular disease (ASCVD) within the next 10 years [6]. - A dedicated trial (REDEFINE 3) is ongoing to further investigate CagriSema's effects on cardiovascular outcomes in patients with established cardiovascular disease [4][6]. Group 3: Safety Profile - Safety data from the REDEFINE 1 trial indicated low discontinuation rates due to adverse events, with 6% for CagriSema compared to 3.7% for placebo [4]. - Adverse events were primarily gastrointestinal, with nausea (55% vs. 12.6% for placebo), constipation (30.7% vs. 11.6%), and vomiting (26.1% vs. 4.1%), mostly mild-to-moderate in severity [4]. Group 4: Product Information - CagriSema is a fixed-dose combination of cagrilintide (2.4 mg) and semaglutide (2.4 mg), being investigated for adults with overweight or obesity and type 2 diabetes [7][8]. - The REDEFINE 1 trial involved 3,417 adults with obesity or overweight and one or more obesity-related comorbidities, without type 2 diabetes [8].